Breast Care最新文献

{"title":"Magnetic Marker Artefacts on Magnetic Resonance Imaging and Localization Precision: Considerations for Targeted Axillary Dissection after Neoadjuvant Therapy.","authors":"Muharrem Oner, Kefah Mokbel","doi":"10.1159/000546482","DOIUrl":"https://doi.org/10.1159/000546482","url":null,"abstract":"","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 5","pages":"375-377"},"PeriodicalIF":2.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145343599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should Sonographic Abnormal Axillary Lymph Nodes Be Excised in Sentinel Node Biopsy of Breast Cancer?","authors":"Xing Wang, Zhaoqing Fan, Ling Huo, Tie Fan, Xinguang Wang, Wei Cao, Yingjian He, Tao Ouyang","doi":"10.1159/000548074","DOIUrl":"10.1159/000548074","url":null,"abstract":"<p><strong>Background: </strong>In sentinel node biopsy (SNB) procedure for breast cancer patient, whether the abnormal node was excised is uncertain. The impact of abnormal node on the accuracy of SNB results is unknown.</p><p><strong>Methods: </strong>In this prospective study, breast cancer patients with sonographically abnormal axillary lymph nodes (SAALNs) and negative FNAC results were eligible. Before the SNB operation, a localization wire was placed at the SAALN by ultrasound guidance. In the SNB operation, the wire-localized nodes (WLNs) and radioactive nodes were excised and labeled separately for pathological examination.</p><p><strong>Results: </strong>In total, 213 WLNs, 169 (79.3%) were sentinel nodes (SNs) and 44 (20.7%) were non-SNs. 79 (37.1%) patients had positive SNs and 63 (29.6%) patients had positive WLNs both identified by pathological examination. 80 (37.6%) patients had positive lymph nodes whether it was SNs or WLNs. Omission diagnosis rate of SNB was 1.3% (1/80). Three axillary recurrence events (3/133, 2.3%) occurred in SN and WLN both negative patients at a median follow-up time of 132 months.</p><p><strong>Conclusions: </strong>Performing SNB by excising the SAALNs with negative FNAC simultaneously in breast cancer patients could reduce the omission diagnosis rate marginally, and the risk of axillary local recurrence is low.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Continuous Care Combined with Dietary Care on Sleep Quality and Quality of Life in Patients with Breast Cancer Fatigue.","authors":"Zhining Yu, Li Song, Xingrui Wei, Lifang Wang, Liping Cui","doi":"10.1159/000548024","DOIUrl":"10.1159/000548024","url":null,"abstract":"<p><strong>Objective: </strong>Patients with breast cancer fatigue-related fatigue have significantly reduced sleep quality and quality of life. Continuous care combined with dietary care has been shown to improve sleep quality and quality of life in patients with malignant tumor. However, its effects on breast cancer patients undergoing radiotherapy have not been fully explored.</p><p><strong>Methods: </strong>Eighty breast cancer patients with fatigue were treated in our hospital from April 2020 to June 2022 and randomly divided into a control group (<i>n</i> = 40) and an observation group (<i>n</i> = 40). The control group received routine nursing care, while the observation group received continuous nursing combined with dietary nursing. Sleep quality, quality of life, compliance behavior, and nursing satisfaction were compared between the two groups.</p><p><strong>Results: </strong>The Pittsburgh Sleep Quality Scale scores of both groups were lower after intervention than before, and the observation group's Pittsburgh Sleep Quality Index was lower than that of the control group (<i>p</i> < 0.05). After intervention, Generic Quality Of Life Inventory-74 scores of both groups were higher than before intervention, and the observation group's score was higher than the control group (<i>p</i> < 0.05). The reasonable diet rate, treatment compliance rate, regular follow-up rate, and regular lifestyle in the observation group were significantly higher than those in the control group (<i>p</i> < 0.05). The nursing satisfaction of the observation group was 95.00%, significantly higher than that of the control group (80.00%, <i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Continuous nursing combined with dietary nursing can significantly improve sleep quality and quality of life, as well as improve compliance behaviors and nursing satisfaction of patients with breast cancer fatigue, indicating significant clinical value.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer-Related Lymphedema: A Common Challenge among Nigerian Breast Cancer Survivors.","authors":"Olalekan Olasehinde, Funmilola Wuraola, Matteo Di Bernardo, Gregory Knapp, Adewale Aderounmu, Adeleye Omisore, Ayodeji Oladele, Mercy Omotola Awe, Tajudeen Mohammed, Anya Romanoff, T Peter Kingham, Victoria Mango, Adewale Adisa, Olusegun Alatise","doi":"10.1159/000547583","DOIUrl":"10.1159/000547583","url":null,"abstract":"<p><strong>Background: </strong>Lymphedema is one of the most prevalent yet under-recognized complication of breast cancer treatment, with its prevalence largely unexplored in Nigeria and across much of sub-Saharan Africa.</p><p><strong>Methods: </strong>A cross-sectional study was conducted among breast cancer survivors at least 6 months post-mastectomy and axillary lymph node dissection. Lymphedema was diagnosed using multiple methods: patient-reported arm swelling, arm measurements (≥2 cm difference compared to the contralateral arm), a >10% difference in extracellular water (ECW) using bioimpedance analysis, and a lower threshold of 5% to capture subclinical lymphedema. Using patient report as the gold standard, the accuracy of the various diagnostic methods was assessed. The relationship between clinical variables and lymphedema was tested using univariate logistic regression analysis.</p><p><strong>Results: </strong>Fifty-one patients with a median age of 51 years and a median duration of 40 months post-surgery (10-62 months) were evaluated. The prevalence of lymphedema was 39.2% based on symptoms, 33% using arm measurements, 22.2% using bioimpedance analysis at a threshold of >10% difference in ECW, and 46.7% at a threshold of 5%. An ECW difference of >5% had the highest sensitivity (65%), while an ECW difference at 10% threshold had the best specificity (89%). Obesity was the only clinical variable associated with lymphedema in this cohort (<i>p</i> = 0.018).</p><p><strong>Conclusion: </strong>Breast cancer-related lymphedema (BCRL) appears common among Nigerian breast cancer patients. Its occurrence should be preempted, particularly in obese patients in whom preventive measures may be instituted. These findings highlight the potential value of incorporating BCRL awareness and management into breast cancer care in Nigeria.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Sentinel Lymph Node Biopsy with Blue Dye Only after Neoadjuvant Systemic Treatment in Patients with Breast Cancer Who Had Biopsy-Proven Node-Positive Disease at Admission: SENATURK-ROSANNA Study.","authors":"Aysegul Aktas, Meryem Gunay Gurleyik, Guldeniz Karadeniz Cakmak, Hasan Karanlik, Sibel Ozkan Gurdal, M Umit Ugurlu, Atakan Sezer, Bahadir M Gulluoglu","doi":"10.1159/000548046","DOIUrl":"10.1159/000548046","url":null,"abstract":"<p><strong>Introduction: </strong>In breast cancer patients with initially metastatic axillary lymph nodes (pN+, ALNs), neoadjuvant systemic treatment (NST) significantly downstages axillary disease. Sentinel lymph node biopsy (SLNB) in well-responded patients has been associated with high false-negative rates (FNRs) when less than 3 nodes are retrieved and a single tracer is used. Targeted axillary dissection after node clipping has been proposed to reduce FNR but is costly, is labor intensive, and requires specialized equipment. However, there is limited evidence linking high FNR with worse long-term oncological outcomes, such as recurrence rates. This study evaluates axillary recurrence rates in breast cancer patients downstaged by NST and assessed with SLNB using blue dye alone.</p><p><strong>Methods: </strong>We retrospectively analyzed clinical, pathological, and follow-up data from 245 breast cancer patients treated between 2010 and 2021 across six centers in Turkiye. All patients had pN+, ALNs at diagnosis and were downstaged to ypN0 or ypN0[i+] by SLNB with blue dye after NST. Recurrence rates in the breast, axilla, other regional lymphatics, distant organs, and mortality were recorded.</p><p><strong>Results: </strong>Of the 245 patients, 10% had cN2 disease and 35% had less than 3 sentinel lymph nodes retrieved. After SLNB, 6% had isolated tumor cells in their nodes, while the rest achieved a pathologic complete response. The median follow-up was 51 months. Only 2% developed ipsilateral axillary recurrence (0.8% isolated), and 18% had any recurrence, primarily as distant metastasis. The mortality rate was 9%.</p><p><strong>Conclusion: </strong>Our study demonstrates that performing SLNB after NST using only blue dye may be a viable and acceptable approach in clinical practice. The oncological safety and adequacy of this simple method should be confirmed with further studies.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Glycation End Products: A Promising Prognostic Indicator in Breast Cancer Patients.","authors":"Gülcin Sahingoz Erdal, Nilgun Isiksacan, Murat Cikot, Mustafa Yaman, Esra Yildirim Servi, Elif Ede Cintosun, Sevgi Kalkanli Tas, Tamay Seda Tasci, Nursel Kocamaz, Dilay Karabulut","doi":"10.1159/000547938","DOIUrl":"10.1159/000547938","url":null,"abstract":"<p><strong>Introduction: </strong>Advanced glycation end products (AGEs) form through long-term reactions between proteins/lipids and sugars, accumulating in tissues and contributing to disease. AGEs are linked to cancer progression, with studies showing associations with colon and pancreatic cancer.</p><p><strong>Methods: </strong>This study investigates the relationship between AGEs and breast cancer. Stage 2-3 breast cancer patients and age-matched healthy controls were included. Exclusion criteria were diabetes, renal/liver disease, chronic inflammation, and infection. Blood samples were collected from patients pre-surgery and 48 h post-surgery and once from fasting controls. Glyoxal (GO) and methylglyoxal (MGO) levels were measured via liquid chromatography. A total of 60 breast cancer patients and 21 controls participated.</p><p><strong>Results: </strong>GO and MGO levels were significantly higher in patients than controls (<i>p</i> < 0.001) and decreased post-surgery. No significant differences were found between breast cancer subtypes. AGE levels did not correlate with age, lymph node involvement, or menopause status.</p><p><strong>Conclusion: </strong>The significant drop in AGE levels post-surgery suggests tumor burden influences AGE levels. While their predictive value remains uncertain, AGEs could serve as prognostic biomarkers. Monitoring AGEs may encourage lifestyle changes, and rising levels might indicate cancer recurrence or progression.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000547496","DOIUrl":"https://doi.org/10.1159/000547496","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000546080.].</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Perspectives in the Management of Triple-Negative Breast Cancer.","authors":"Rupert Bartsch, Zsuzsanna Bago-Horvath, Daniel Egle, Simon P Gampenrieder, Birgit Grünberger, Sonja Heibl, Maximilian Marhold, Caroline Preuss, Gabriel Rinnerthaler, Kathrin Strasser-Weippl, Christoph Suppan, Christian F Singer, Michael Gnant","doi":"10.1159/000547988","DOIUrl":"10.1159/000547988","url":null,"abstract":"<p><strong>Background: </strong>The biological heterogeneity of triple-negative breast cancer (TNBC) and the availability of a growing number of therapeutic options necessitate continuous redefinition of the ideal treatment algorithm for patients with TNBC. Austrian experts convened for an advisory board meeting in November 2024 to discuss standards of care in the early and metastatic settings with a focus on the healthcare situation in Austria.</p><p><strong>Summary: </strong>This paper discusses biological principles, (neo)adjuvant treatment standards and strategies of escalation and de-escalation, as well as standards of care, new treatment options, and the management of central nervous system (CNS) disease in the setting of metastatic TNBC.</p><p><strong>Key messages: </strong>TNBC remains a high-risk subtype of breast cancer. Neoadjuvant chemotherapy is preferred in early-stage disease starting from cT1c, cN0, with the addition of pembrolizumab recommended from clinical stage II. Post-neoadjuvant treatment is guided by the pathological response and <i>BRCA</i> mutation status, while ongoing trials are evaluating the role of antibody-drug conjugates in this setting. In metastatic TNBC, assessment of PD-L1 expression and <i>BRCA</i> mutation status is essential for optimal sequencing of available treatment options. CNS involvement remains a major clinical challenge.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Therapy on Health-Related Quality of Life in Breast Cancer Patients >60 Years.","authors":"Maximiliane Burgmann, Valerie Schlager, Annika Lotz, Kerstin Hermelink, Thomas Kolben, Christina Seifert, Franziska Ganster, Sven Mahner, Nadia Harbeck, Rachel Wuerstlein","doi":"10.1159/000547600","DOIUrl":"10.1159/000547600","url":null,"abstract":"<p><strong>Introduction: </strong>Since the risk of developing breast cancer (BC) increases with age, it is primarily a challenge for the older population. Older patients are often affected by comorbidities and frailty. The aim of this study was to determine the impact of adjuvant therapy on quality of life in older BC patients, considering their global health status including comorbidities.</p><p><strong>Methods: </strong>All BC patients aged 60 years old and above at initial diagnosis, who had been treated at the Breast Center of the LMU University Hospital of Munich, Germany, between 2010 and 2013, were eligible for participation. Quality of life was assessed by validated questionnaires. With a self-developed questionnaire, we assessed patients' general health status, oncological therapy as well as the Barthel Index and Charlson Comorbidity Index (CCI) as instruments of the geriatric assessment.</p><p><strong>Results: </strong>Data collected from 276 patients were included. Health-related quality of life (HRQoL) was affected by chemotherapy in the areas of physical function, mobility, fatigue, burden of disease, and financial difficulties. Regarding endocrine therapy, HRQoL was only affected in the area of burden of disease. A higher CCI and BMI as well as polymedication were significantly correlated with worse HRQoL.</p><p><strong>Conclusion: </strong>This cross-sectional, retrospective analysis indicates that chemotherapy affects HRQoL negatively in several quality of life areas in the first 3 years after the initial diagnosis of BC. CCI, obesity, and polymedication also impact on HRQoL. This knowledge should be incorporated into the treatment decision-making process and targeted measures should be offered to support older patients.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistence to Adjuvant Endocrine Therapy for Breast Cancer in Botswana: An Observational Cohort Analysis.","authors":"Arthur T Johnson, Peter Vuylsteke, Taolo Ntloedibe, Jose Euberto Mendez Reyes, Oaitse John, James R Wester, Elizabeth Y Chiao, Scott L Dryden-Peterson","doi":"10.1159/000547028","DOIUrl":"10.1159/000547028","url":null,"abstract":"<p><strong>Purpose: </strong>Daily use of adjuvant endocrine therapy significantly reduces the risk of recurrence and death of estrogen-positive breast cancer; however, it remains unclear to what degree patients persist with endocrine therapy in southern Africa.</p><p><strong>Methods: </strong>Female patients, >18 years of age, with estrogen receptor-positive breast cancer within the Thabaste Cancer Cohort in Botswana were identified and contacted to determine if they remained persistent to their adjuvant endocrine therapy. Non-persistence was defined as self-reported discontinuation of endocrine therapy for longer than 180 days. Clinical and demographic data were compared between persistent and nonpersistent patients.</p><p><strong>Results: </strong>Overall, 133 patients with estrogen receptor-positive breast cancer were identified of which 91 were prescribed adjuvant endocrine therapy. Tamoxifen was prescribed for 56 (63%) and anastrozole for 33 (37%) women. Adjuvant endocrine therapy was interrupted in 45 (50%) patients; however, only 8 (8.8%) were nonpersistent. Sociodemographic and clinical characteristics were similar between persistent and nonpersistent patients, except significantly higher income was noted in those persistent to endocrine therapy. Medication non-availability was the most common reason noted for interruption of endocrine therapy.</p><p><strong>Conclusion: </strong>Interruptions to adjuvant endocrine therapy in Botswana is common, but rates of persistence remain high. Medication stockout was the most common reasons for interruption of adjuvant endocrine therapy.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145249853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}